Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Scaling Up ADC Payloads | Contract Pharma

What are you searching for?

Sign in
Sponsored Content

Scaling Up ADC Payloads

Learn more about the scale up of antibody drug conjugates payloads by viewing this webinar.

Released By Lonza

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications. They are made of a payload, a linker, and an antibody. Usually, they are classified as Highly Potent APIs (HPAPIs) compounds due to the payload. Handling and manufacturing can be challenging due to the strict requirements for containment. As more of these complex products enter clinical development, the need to scale up production of their payloads becomes a pressing topic. In this webinar, participants will hear about Lonza’s investment in facilities capable of producing large quantities (100+ kg) under the strictest levels of containment.

  • Market drivers
  • Design concepts
  • Facility overview

Key Learning Objectives:
  • Key market trends
  • Lonza’s approach to lifecycle investment
  • Leadership in highly-potent API facility and process design
Register Now!

Request more information from Lonza

Request more information from Lonza

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics